Steven Gitelis, M.D. and Rush University Medical Center in Chicago, Illinois, are the inaugural contributors to a landmark Surgical Oncology Research Team (SORT) Registry.
Cloud-Based Ortho Oncology Registry Launched
1 min read Premium comments
Secondary#bone#sortregistry
The sponsor of the registry, ONKOS Surgical, told OTW that this is the first registry of its kind and is designed to function as a multicenter platform to prospectively collect functional, psychosocial and oncological outcome data.
“This is a major milestone for the musculoskeletal oncology community of surgeons and patients as well as for ONKOS Surgical.” said Patrick Treacy, company CEO and co-founder.
“When we started our company, we made a commitment that we would place a large investment in collecting prospective outcomes for the musculoskeletal oncology patient. The SORT Registry is a cloud-based platform that will allow surgeons to collect prospective data and collaborate with other institutions to drive larger data sets.”
ONKOS is the first and only company to invest in a registry of this kind.
Steven Gitelis, M.D., ONKOS Surgical chief medical officer and associate dean for Surgical Services at Rush University said, “This is an unprecedented opportunity for my musculoskeletal oncology colleagues to collaborate in a way that will answer important questions.”
“The SORT Registry provides a research platform that will enable individual institutions to prospectively collect their own data while partnering with other leading institutions around the country to answer questions that will potentially impact how we treat patients in the future. In the past, small data sets have impacted the ability to truly change the paradigm of patient care. This registry has the potential to change that.”
Dr. Gitelis, also a professor in the Department of Orthopedic Surgery at Rush, told OTW, “The SORT Registry will be collecting functional scores using the Musculoskeletal Tumor Society (MSTS) functional evaluation tool and PROMIS [Patient-Reported Outcomes Measurement Information System) scores, which are patient reported outcomes both at presentation and follow up. The PROMIS scores incorporate psychosocial factors. These measurement tools will give us a good indication of our outcomes managing patients with musculoskeletal tumors.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.